German pharmaceutical giant Bayer’in shares were listed on the London Stock Exchange on Tuesday morning after the company increased demand for new cancer and kidney drugs in the first quarter of 2025. %It's up 10 and a half.
Interest, tax, depreciation and pre-depreciation earnings (EBITDA) before special items amounted to €4.1 billion in the first quarter of 2025. This is compared to the same quarter of the previous year. spite a 7.4-decrease, it was still above market expectations of €3.9 billion, according to Bloomberg’.
Group sales in the first quarter compared to the same quarter of 2024 %-0.1 billion euros, down 13.7 billion euros. If the core gain per share is %It declined 11.7 to 2.5 Euro’.
Bayer’'s CEO, Bill Anderson, was optimistic that the increase in earnings in the pharmaceutical division was a sign that teams were learning to do more with less. He also reiterated his confidence in the company's fundamentals and the momentum of its launches.
The company also said it is closely monitoring ongoing economic and geopolitical changes, as well as their impact on the company.
Bayer has confirmed its outlook for 2025 at constant rates and expects the pharmaceutical division to perform at the top of its previously shared sales and profitability expectation range.
Bayer’in pharmaceutical division grows as plant science slows
Although sales of the Bayer’in pharmaceutical division lagged behind the European, Middle East and African (EMEA) region, they were mainly driven by North American sales in the first quarter of 2025. %It's up 4.4.
The company's new hormone therapy drug for prostate cancer, Nubeqa, has seen significant demand along with Kerendia, which is used to treat chronic kidney disease.
While sales of Eylea’, which is mainly used to treat various eye conditions, have also increased, the Bayer’in radiology business has also been strong. Similarly, birth control drugs such as SUMMER and Mirena also saw strong growth. However, the anticoagulant Xarelto’ saw a decline, mainly due to the expiration of the patent.
On the other hand, sales at the plant science branch of Bayer’in in the first quarter of the year, in part due to the slowdown in the demand for pesticides %4.1 is down. The ongoing low prices of glyphosate, the active ingredient of the Roundup weed killer, also contributed to a decline in plant science performance.
The company had previously shared that it could potentially halt glyphosate production in Louisiana’ as Chinese competition intensified.
Bayer also continues to deal with significant lawsuits related to products that the company took over during its acquisition of Monsanto’ in 2018.
